Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRK 
Merck & Company Inc (MRK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: MRK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $102.33
1 Year Target Price $102.33
| 12 | Strong Buy |
| 3 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.17% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 206.84B USD | Price to earnings Ratio 12.76 | 1Y Target Price 102.33 |
Price to earnings Ratio 12.76 | 1Y Target Price 102.33 | ||
Volume (30-day avg) 26 | Beta 0.38 | 52 Weeks Range 72.58 - 116.25 | Updated Date 09/14/2025 |
52 Weeks Range 72.58 - 116.25 | Updated Date 09/14/2025 | ||
Dividends yield (FY) 3.71% | Basic EPS (TTM) 6.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 25.79% | Operating Margin (TTM) 37.47% |
Management Effectiveness
Return on Assets (TTM) 13.01% | Return on Equity (TTM) 35.42% |
Valuation
Trailing PE 12.76 | Forward PE 8.45 | Enterprise Value 233621427702 | Price to Sales(TTM) 3.25 |
Enterprise Value 233621427702 | Price to Sales(TTM) 3.25 | ||
Enterprise Value to Revenue 3.67 | Enterprise Value to EBITDA 9.33 | Shares Outstanding 2497779968 | Shares Floating 2493836714 |
Shares Outstanding 2497779968 | Shares Floating 2493836714 | ||
Percent Insiders 0.07 | Percent Institutions 80.59 |
Upturn AI SWOT
Merck & Company Inc
Company Overview
History and Background
Merck & Company, Inc., founded in 1891 as the U.S. affiliate of the German company Merck KGaA, became independent during World War I. A leading pharmaceutical company, Merck has a long history of developing innovative medicines and vaccines.
Core Business Areas
- Pharmaceuticals: Human health pharmaceuticals, including prescription medicines and vaccines for various therapeutic areas.
- Animal Health: Veterinary pharmaceuticals, vaccines, and related animal health products and services.
Leadership and Structure
Robert M. Davis is the Chairman, President, and Chief Executive Officer. The company has a traditional hierarchical structure with various divisions and departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Keytruda: A humanized antibody used in cancer immunotherapy. Competitors include Bristol Myers Squibb's Opdivo and Roche's Tecentriq. Keytruda generated ~$25 billion in revenue in 2023
- Gardasil: A vaccine that protects against HPV. Competitors include GSK's Cervarix. Gardasil generated ~$9 billion in revenue in 2023.
- Januvia/Janumet: Diabetes medication. Competitors include Novo Nordisk and Eli Lilly diabetes treatments. Revenue is declining due to patent expiration and generic competition.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense R&D, stringent regulatory oversight, and increasing pressure on drug pricing.
Positioning
Merck is a major player in the pharmaceutical industry, known for its innovative drugs and vaccines and its strong presence in oncology and animal health.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at over $1.4 trillion and is expected to grow. Merck is well-positioned within key therapeutic areas to capture a significant share of this TAM.
Upturn SWOT Analysis
Strengths
- Strong oncology portfolio (Keytruda)
- Established global presence
- Robust R&D pipeline
- Strong animal health business
Weaknesses
- Dependence on Keytruda revenue
- Patent expirations of key drugs
- Exposure to drug pricing pressures
- High R&D costs
Opportunities
- Expanding into new therapeutic areas
- Strategic acquisitions and partnerships
- Growth in emerging markets
- Developing innovative drug delivery systems
Threats
- Generic competition
- Regulatory changes
- Biosimilar competition
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- ABBV
- NVS
- LLY
- BMY
- MRNA
Competitive Landscape
Merck faces intense competition from other major pharmaceutical companies, particularly in oncology and other key therapeutic areas. Its strengths include its innovative products and global reach.
Major Acquisitions
Prometheus Biosciences
- Year: 2023
- Acquisition Price (USD millions): 10800
- Strategic Rationale: To bolster its immunology pipeline with a late-stage asset targeting ulcerative colitis and Crohn's disease.
Growth Trajectory and Initiatives
Historical Growth: Merck has experienced growth driven by key products like Keytruda and Gardasil. Data is not available as of this cut-off date.
Future Projections: Analysts project continued growth for Merck, driven by its oncology portfolio and pipeline. Data is not available as of this cut-off date.
Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships, and investments in R&D.
Summary
Merck is a strong player in the pharmaceutical industry, driven by its successful oncology franchise and animal health business. Keytruda's performance is a major strength but also a risk. Strategic acquisitions and R&D investment are crucial to offset patent expirations and maintain growth in a competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions are dynamic and change frequently.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merck & Company Inc
Exchange NYSE | Headquaters Rahway, NJ, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Robert M. Davis J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 73000 | Website https://www.merck.com |
Full time employees 73000 | Website https://www.merck.com | ||
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.